<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03750175</url>
  </required_header>
  <id_info>
    <org_study_id>KFE1713</org_study_id>
    <nct_id>NCT03750175</nct_id>
  </id_info>
  <brief_title>OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -</brief_title>
  <acronym>OPTIPAL-II</acronym>
  <official_title>OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer - Feasibility Study Investigating Circulating Tumor DNA for Treatment Decisions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karen-Lise Garm Spindler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will investigate the feasibility and clinical value of using circulating
      tumor DNA as selection for anti-epidermal growth factor receptor treatment for metastatic
      colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of this prospective study is to investigate if cfDNA in plasma is feasible
      and reliable for selection of mCRC patients who will benefit of anti-EGFR monoclonal antibody
      therapy

      Secondary, to analyze developments in mutational status as reflected by cfDNA in plasma
      during therapy and at time of progression
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of ctDNA analysis for RAS mutation analysis</measure>
    <time_frame>maximum 7 days</time_frame>
    <description>Feasibility measures
Identification of wildtype or mutated status and results delivered to clinicians
Initial clinical test results i.e. ctDNA mutations or wildtype status within 7 days
Detailed mutation type characterization is provided retrospectively.
Failure parameters
Quality of samples; PB &gt; 5%, CPP1 major loss &lt; 10%
Transportation &gt; 3 week days
Analysis &gt; 3 working days
Total results delivered &gt; 7 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retrospective concordance analysis</measure>
    <time_frame>By end of study, expected after 3 years</time_frame>
    <description>Retrospective comparison of tumor mutation and plasma mutation analysis at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>1 year</time_frame>
    <description>Rate of disease control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resistance mutations</measure>
    <time_frame>At time of progression, data analysis expected after 3 years</time_frame>
    <description>Rate of Ectoderm mutations at time of progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lead time</measure>
    <time_frame>At time of progression, data analysis expected after 3 years</time_frame>
    <description>Calcualted lead time between radiologically detected progression and molecular biologically detected ( by Ectoderm and other resistance mutations) in the ctDNA.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <condition>Circulating Tumor DNA</condition>
  <condition>KRAS Gene Mutation</condition>
  <condition>NRAS Gene Mutation</condition>
  <condition>BRAF Gene Mutation</condition>
  <condition>Epidermal Growth Factor Receptor Inhibitor</condition>
  <arm_group>
    <arm_group_label>Colorectal cancer patients</arm_group_label>
    <description>Clinical utility of ctDNA analysis for treatment decision
Use of ctDNA for KRAS, NRAS and BRAF testing prior to potential anti-EGFR monoclonal antibody treatment for metastatic colorectal cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Plasma circulating DNA analysis</intervention_name>
    <description>Clinical utility of ctDNA analysis for treatment decision</description>
    <arm_group_label>Colorectal cancer patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma samles for circulating DNA analysis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic colorectal cancer and indication for palliative chemotherapy with
        potential anti-EGFR monoclonal antibody.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Histopathologically verified metastatic colorectal cancer

          -  Indication for systemic palliative treatment with standard Anti-EGFR monoclonal
             antibodies

          -  Fit for therapy with EGFR inhibition

          -  Consent to treatment and sampling

          -  Measureable disease according to RECIST v 1.1

          -  Age â‰¥ 18

        Exclusion criteria

          -  PS &gt; 2

          -  Significant other cancer disease within 5 years of inclusion

          -  Conditions precluding sampling during therapy and treatment breaks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen-Lise G Spindler</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology, AUH, Dk</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen-Lise G Spindler</last_name>
    <phone>004578462390</phone>
    <email>k.g.spindler@rm.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>September 27, 2018</study_first_submitted>
  <study_first_submitted_qc>November 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2018</study_first_posted>
  <last_update_submitted>November 20, 2018</last_update_submitted>
  <last_update_submitted_qc>November 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Karen-Lise Garm Spindler</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

